Moreover, clinical data based on immunohistochemistry of various tumor types show that CA IX is frequently associated with cancer progression and poor prognosis and in some tumor tissues it is co-expressed with the markers of oncogenic metabolism and acidosis, such as LDH5, GLUT1, MCT4 etc. (Beasley et al., 2001; Koukourakis et al., 2006a,b; Rajaganeshan et al., 2009; Rademakers et al., 2011; Kim et al., 2013). The gene discussed is SLC16A3; the disease is neoplasm.